A Review of Vinorelbine in the Treatment of Breast Cancer
- 1 July 2001
- journal article
- review article
- Published by Elsevier in Clinical Breast Cancer
- Vol. 2 (2) , 113-128
- https://doi.org/10.3816/cbc.2001.n.016
Abstract
No abstract availableKeywords
This publication has 47 references indexed in Scilit:
- Cost-Utility Analysis of Chemotherapy Using Paclitaxel, Docetaxel, or Vinorelbine for Patients With Anthracycline-Resistant Breast CancerJournal of Clinical Oncology, 1999
- Differential in vitro association of vinca alkaloid-induced tubulin spiral filaments into aggregated spiralsBiochemical Pharmacology, 1999
- Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or olderAnnals of Oncology, 1999
- Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer.Journal of Clinical Oncology, 1997
- Phase II Trial of Weekly IV Vinorelbine as a Single Agent in First-Line Advanced Breast Cancer ChemotherapyAmerican Journal of Clinical Oncology, 1995
- Vinorelbine: A novel vinca alkaloidAmerican Journal of Health-System Pharmacy, 1995
- Phase II trial of weekly IV vinorelbine in first-line advanced breast cancer chemotherapyAnnals of Oncology, 1994
- A phase II, multicentre, UK study of vinorelbine in advanced breast cancerBritish Journal of Cancer, 1994
- Vinorelbine (Navelbine) as a salvage treatment for advanced breast cancerAnnals of Oncology, 1994
- Immunofluorescence study of the action of navelbine, vincristine and vinblastine on mitotic and axonal microtubulesInternational Journal of Cancer, 1990